Table 2.
Top ten best-selling innovative drugs worldwide in 2016*
| # | Drug (generic name) | Class | Molecular target** | Company | Primary indications (abbreviated) | 2015 worldwide sales | 2016 worldwide sales | Percent change |
|---|---|---|---|---|---|---|---|---|
| 1 | Humira® (adalimumab) | mAb | TNF (TNF-α) | Abbvie | RA, psoriasis, IBD, others | $14,012 M | $16,078 M | +14.7% |
| 2 | Harvoni® (ledipasvir/sofosbuvir) | SM | HCV NS5B polymerase, NS5A | Gilead Sciences | HCV infection | $13,864 M | $9,081 M | −34.5% |
| 3 | Enbrel® (etanercept) | Fc fusion | TNF (TNF-α) | Amgen, Pfizer | RA, psoriasis, others | $8,697 M | $8,874 M | +2.0% |
| 4 | Rituxan® (rituximab) | mAb | MS4A1 (CD20) | Roche, Biogen | B cell malignancies, RA | $8,354 M | $8,583 M | +2.7% |
| 5 | Remicade® (infliximab) | mAb | TNF (TNF-α) | J&J, Merck | RA, psoriasis, IBD, others | $8,760 M | $6,561 M | −10.6% |
| 6 | Revlimid® (lenalidomide) | SM | CRBN (E3 ligase cereblon), IKZF1, IKZF3 | Celgene | Multiple myeloma | $5,801 M | $6,974 M | +20.2% |
| 7 | Avastin® (bevacizumab) | mAb | VEGF | Roche | MCRC, MRCC, others | $6,654 M | $6,752 M | +1.5% |
| 8 | Herceptin® (trastuzumab) | mAb | ERBB2 (HER2) | Roche | HER2+ breast cancer, gastric cancer, others | $6,509 M | $6,751 M | +3.7% |
| 9 | Lantus® (insulin glargine) | Protein | INSR (insulin receptor) | Sanofi | T1D, T2D | $6,770 M | $6,054 M | −10.6% |
| 10 | Prevnar 13® (pneumococcal 13-valent conjugate vaccine; CRM197) | Vaccine (conjugated) | Pneumococcal polysaccharides | Pfizer | Pneumonia prophylaxis | $6,245 M | $5,718 M | −8.4% |
Abbreviations: CRM197, non-toxic mutant form of diphtheria toxin; mAb, monoclonal antibody; SM, small molecule; J&J, Johnson & Johnson; RA, rheumatoid arthritis; IBD, intestinal bowel disease; HCV, hepatitis C virus; MCRC, metastatic colorectal cancer; MRCC, metastatic renal cell carcinoma; HER2, human epidermal growth factor receptor-2; T1D, type 1 diabetes; T2D, type 2 diabetes
* Data abstracted from La Merie, 2017
** Names given as HUGO Gene Nomenclature Committee (HGNC) names (Gray et al., 2015) followed by commonly used names in parentheses